ONVO vs. BCDA, IKT, GENE, SRNE, COEP, MBOT, TTNP, CELZ, SNTI, and CHRO
Should you be buying Organovo stock or one of its competitors? The main competitors of Organovo include BioCardia (BCDA), Inhibikase Therapeutics (IKT), Genetic Technologies (GENE), Sorrento Therapeutics (SRNE), Coeptis Therapeutics (COEP), Microbot Medical (MBOT), Titan Pharmaceuticals (TTNP), Creative Medical Technology (CELZ), Senti Biosciences (SNTI), and Chromocell Therapeutics (CHRO). These companies are all part of the "medical" sector.
Organovo (NASDAQ:ONVO) and BioCardia (NASDAQ:BCDA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, community ranking, institutional ownership, valuation, analyst recommendations, risk and media sentiment.
8.2% of Organovo shares are owned by institutional investors. Comparatively, 20.6% of BioCardia shares are owned by institutional investors. 4.0% of Organovo shares are owned by company insiders. Comparatively, 23.9% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Organovo received 186 more outperform votes than BioCardia when rated by MarketBeat users. Likewise, 50.65% of users gave Organovo an outperform vote while only 47.62% of users gave BioCardia an outperform vote.
In the previous week, BioCardia had 1 more articles in the media than Organovo. MarketBeat recorded 2 mentions for BioCardia and 1 mentions for Organovo. BioCardia's average media sentiment score of 0.50 beat Organovo's score of 0.36 indicating that BioCardia is being referred to more favorably in the news media.
BioCardia has a consensus target price of $4.00, indicating a potential upside of 962.13%. Given BioCardia's higher probable upside, analysts clearly believe BioCardia is more favorable than Organovo.
Organovo has a net margin of 0.00% compared to BioCardia's net margin of -2,425.79%. Organovo's return on equity of -182.88% beat BioCardia's return on equity.
BioCardia has higher revenue and earnings than Organovo. BioCardia is trading at a lower price-to-earnings ratio than Organovo, indicating that it is currently the more affordable of the two stocks.
Organovo has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500. Comparatively, BioCardia has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.
Summary
BioCardia beats Organovo on 10 of the 17 factors compared between the two stocks.
Get Organovo News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ONVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organovo Competitors List
Related Companies and Tools
